Precision BioSciences, Inc. (DTIL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1235720,
    "name": "Precision BioSciences, Inc.",
    "stock_name": "Precision BioSciences, Inc.",
    "full_name": "Precision BioSciences, Inc.",
    "name_url": "stocks-analysis/precision-biosciences-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.02",
    "chg": 0.23,
    "chgp": "4.8%",
    "dir": 1,
    "prev_price": "4.79",
    "mcapval": "58.72",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US74019P2074",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "389.74 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/precision-biosciences-inc-1235720-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Precision BioSciences Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/precision-biosciences-forms-golden-cross-signaling-potential-bullish-breakout-3607913",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PrecisionBioSci_goldencross_3607913.png",
        "date": "2025-10-09 16:50:02",
        "description": "Precision BioSciences, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Current technical indicators suggest a mildly bullish outlook, with positive trends in daily moving averages. Despite a challenging year, the company has shown resilience with significant year-to-date gains, outperforming the S&P 500."
      },
      {
        "title": "Is Precision BioSciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-precision-biosciences-inc-technically-bullish-or-bearish-3546415",
        "imagepath": "",
        "date": "2025-09-20 19:32:03",
        "description": "As of 21 August 2025, the technical trend for Precision BioSciences, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a sideways trend on the weekly chart and mildly bearish on the monthly chart. The KST indicates a mildly bullish stance weekly but bearish monthly, and the OBV is mildly bearish weekly while bullish monthly. Overall, the indicators suggest a mixed technical stance leaning towards mildly bearish.\n\nIn terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of 28.87% versus the S&P 500's 12.22%, but a significant decline of 48.85% over the past year compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is Precision BioSciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-precision-biosciences-inc-overvalued-or-undervalued-3542996",
        "imagepath": "",
        "date": "2025-09-20 18:07:59",
        "description": "As of 15 May 2025, the valuation grade for Precision BioSciences, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.32, an EV to EBITDA of -0.29, and a ROE of -83.23%. Compared to peers, ImmunoPrecise Antibodies Ltd. has a significantly higher P/E ratio of -13.04, while Marker Therapeutics, Inc. shows a similar risk profile with an EV to EBITDA of 0.0342.\n\nIn terms of stock performance, Precision BioSciences has underperformed relative to the S&P 500, with a one-year return of -48.85% compared to the index's 17.14%. This stark contrast reinforces the notion that the stock is overvalued in its current state...."
      }
    ],
    "total": 8,
    "sid": "1235720",
    "stock_news_url": "https://www.marketsmojo.com/news/precision-biosciences-inc-1235720"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Precision BioSciences Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-09 16:50:02

Precision BioSciences, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Current technical indicators suggest a mildly bullish outlook, with positive trends in daily moving averages. Despite a challenging year, the company has shown resilience with significant year-to-date gains, outperforming the S&P 500.

Is Precision BioSciences, Inc. technically bullish or bearish?

2025-09-20 19:32:03

As of 21 August 2025, the technical trend for Precision BioSciences, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a sideways trend on the weekly chart and mildly bearish on the monthly chart. The KST indicates a mildly bullish stance weekly but bearish monthly, and the OBV is mildly bearish weekly while bullish monthly. Overall, the indicators suggest a mixed technical stance leaning towards mildly bearish. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of 28.87% versus the S&P 500's 12.22%, but a significant decline of 48.85% over the past year compared to the S&P 500's 17.14%....

Is Precision BioSciences, Inc. overvalued or undervalued?

2025-09-20 18:07:59

As of 15 May 2025, the valuation grade for Precision BioSciences, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.32, an EV to EBITDA of -0.29, and a ROE of -83.23%. Compared to peers, ImmunoPrecise Antibodies Ltd. has a significantly higher P/E ratio of -13.04, while Marker Therapeutics, Inc. shows a similar risk profile with an EV to EBITDA of 0.0342. In terms of stock performance, Precision BioSciences has underperformed relative to the S&P 500, with a one-year return of -48.85% compared to the index's 17.14%. This stark contrast reinforces the notion that the stock is overvalued in its current state....

View All News